Cullinan Therapeutics (CGEM) Net Income towards Common Stockholders (2020 - 2026)

Cullinan Therapeutics' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$52.4 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 7.47% year-over-year to -$52.4 million in Q1 2026; TTM through Mar 2026 was -$224.8 million, a 28.16% increase from a year earlier, with the FY2025 full-year figure at -$219.9 million, down 66.39% from the prior year.
• Net Income towards Common Stockholders eased to -$52.4 million in Q1 2026 per CGEM's latest filing, from -$50.7 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $174.1 million in Q2 2022 and bottomed at -$178.5 million in Q4 2024.
• The 5-year median for Net Income towards Common Stockholders is -$45.0 million (2024), against an average of -$38.4 million.
• Biggest YoY gain for Net Income towards Common Stockholders was 1158.85% in 2022; the steepest drop was 1008.53% in 2022.
• Year by year, Net Income towards Common Stockholders stood at -$27.0 million in 2022, then tumbled by 98.86% to -$53.8 million in 2023, then slumped by 231.83% to -$178.5 million in 2024, then soared by 71.62% to -$50.7 million in 2025, then dropped by 3.35% to -$52.4 million in 2026.
• Per Business Quant, the three latest CGEM Net Income towards Common Stockholders figures stand at -$52.4 million (Q1 2026), -$50.7 million (Q4 2025), and -$51.7 million (Q3 2025).